<?xml version="1.0"?>

<document>
	<title>In vitro susceptibility of pseudomonas to four
   beta-lactamantibiotics (ampicillin, cephalothin, carbenicillin,
   piperacillin), to four aminoglycosides (kanamycin, amikacin,
   gentamicin, tobramycin) and to colimycin.</title>

	<author>Hoogkamp-Korstanje-J-A.</author>
	<author>Westerdaal-N-A.</author>

	<source>Chemotherapy. 1979. 25(1). P 48-53.</source>

	<abstract>Of 97 well-defined strains of Pseudomonas, isolated from sputum of
   patients with cystic fibrosis (CF), the minimum inhibitory
   concentration (MIC) of several antibiotics was determined with a
   broth dilution method. The majority of the strains were resistant to
   ampicillin and cephalothin, moderately susceptible to carbenicillin
   (70% to 100 microgram/ml) and highly susceptible to piperacillin
   (100% to 25 microgram/ml, 88% to 6.25 microgram and 60% to 3.12
   microgram/ml). If the pharmacological properties of piperacillin are
   comparable with those of carbenicillin, it can be expected that the
   sputum level of this drug will be adequate to treat Pseudomonas
   pulmonary infections. At the lowest concentration tested (0.78
   microgram/ml) 3% of the strains were susceptible to kanamycin, 85,5%
   to amikacin, 95% to gentamicin, 98% of tobramycin, and 80% to
   colimycin. With regard to clinically attainable concentrations, 98.9%
   of the strains were susceptible to gentamicin and tobramycin 97.9% to
   amikacin, 96.9% to colimycin, 88.6%  to piperacillin, 38% to
   carbenicillin, 25.7% to kanamycin, 12.3% to ampicillin, and 1% to
   cephalothin.</abstract>

	<majorsubject>AMINOGLYCOSIDES: pd</majorsubject>
	<majorsubject>CEPHALOTHIN: pd</majorsubject>
	<majorsubject>COLISTIN: pd</majorsubject>
	<majorsubject>PENICILLINS: pd</majorsubject>
	<majorsubject>PSEUDOMONAS: de</majorsubject>

	<minorsubject>AMIKACIN: pd</minorsubject>
	<minorsubject>AMPICILLIN: pd</minorsubject>
	<minorsubject>CARBENICILLIN: pd</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>COMPARATIVE-STUDY</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: mi</minorsubject>
	<minorsubject>DRUG-RESISTANCE-MICROBIAL</minorsubject>
	<minorsubject>GENTAMICINS: pd</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>KANAMYCIN: pd</minorsubject>
	<minorsubject>MICROBIAL-SENSITIVITY-TESTS</minorsubject>
	<minorsubject>SPUTUM: mi</minorsubject>
	<minorsubject>TOBRAMYCIN: pd</minorsubject>

	<reference>001   BLAIR JE              MANUAL OF CLINICAL MICROBIOLO            970</reference>
	<reference>002   BOXERBAUM B           J INFECT DIS SUPPL             122    59 970</reference>
	<reference>003   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971</reference>
	<reference>004   COWAN ST              MANUAL FOR THE IDENTIFICATION            973</reference>
	<reference>005   ERICSSON HM           ACTA PATH MICROBIOL SCAND     S217       971</reference>
	<reference>006   MARKS MI              J PEDIATR                       79   822 971</reference>
	<reference>007   MONROE PW             APPL MICROBIOL                  18   214 969</reference>
	<reference>008   PENNINGTON JE         ANTIMICROB AGENTS CHEMOTHER      4   299 973</reference>
	<reference>009   PHAIR JP              AM J DIS CHILD                 120    22 970</reference>
	<reference>010   REYNOLDS AV           BR MED J                         3   778 974</reference>
	<reference>011   SAGGERS BA            ARCH DIS CHILD                  43   404 968</reference>
	<reference>012   WOOD RE               PSEUDOMONAS INFECTION IN CF P            975</reference>
	<reference>013   ZIERDT CH             J CLIN MICROBIOL                 1   521 975</reference>

	<citation>1   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER           8   101 981</citation>
	<citation>2   HOOGKAMPKORSTANJE JAA INFECTION                       10  S257 982</citation>
	<citation>3   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983</citation>
	<citation>4   SEGNI G               CURR THER RES CLIN EXP          33   265 983</citation>

</document>
